Differences in antitumor effects of various statins on human pancreatic cancer
- 20 November 2007
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 122 (6), 1214-1221
- https://doi.org/10.1002/ijc.23242
Abstract
Statins are widely used for the treatment of hypercholesterolemia. However, their inhibitory action on HMG-CoA reductase also results in the depletion of intermediate biosynthetic products, which importantly contribute to cell proliferation. The aim of the present study was to compare the effects of the individual commercially available statins on experimental pancreatic cancer. The in vitro effects of individual statins (pravastatin, atorvastatin, simvastatin, lovastatin, cerivastatin, rosuvastatin and fluvastatin) on the viability of human pancreatic cancer were evaluated in CAPAN-2, BxPc-3 and MiaPaCa-2 cell lines. The in vivo experiments were performed on nude mice xenotransplanted with CAPAN-2 cells. The mice received oral treatments either with a placebo, or with the statins mentioned earlier in a daily dose corresponding to a hypocholesterolemic dose in humans. The effect of these statins on the intracellular Ras protein, trafficking in MiaPaCa-2 transfected cells, was also investigated. Substantial differences in the tumor-suppressive effects of all statins were detected in both in vitro and in vivo experiments. While simvastatin exerted the highest tumor-suppressive effects in vitro, rosuvastatin (p = 0.002), cerivastatin (p = 0.002) and fluvastatin (p = 0.009) were the most potent compounds in an animal model. All statins (except pravastatin) inhibited intracellular Ras protein translocation. In summary, substantial tumor-suppressive effects of various statins on the progression of experimental pancreatic adenocarcinoma were demonstrated, with marked differences among individual statins. These results support greatly the potential of statins for the chemoadjuvant treatment of pancreatic cancer.Keywords
Funding Information
- Czech Ministry of Health (NR8132-3)
- Czech Ministry of Education (MSM 6046137305, ME849)
- Czech Science Foundation (204/03/H066)
This publication has 56 references indexed in Scilit:
- Determinants of sensitivity to lovastatin-induced apoptosis in multiple myelomaMolecular Cancer Therapeutics, 2007
- Tissue-specific effects of statins on the expression of heme oxygenase-1 in vivoBiochemical and Biophysical Research Communications, 2006
- Immunohistochemical analysis of heme oxygenase‐1 in preneoplastic and neoplastic lesions during chemical hepatocarcinogenesis§International Journal of Experimental Pathology, 2004
- Effect of statins combined with estradiol on the proliferation of human receptor-positive and receptor-negative breast cancer cellsMenopause, 2003
- Follow-up study of patients randomized in the scandinavian simvastatin survival study (4S) of cholesterol loweringThe American Journal of Cardiology, 2000
- Compactin and Simvastatin, but Not Pravastatin, Induce Bone Morphogenetic Protein-2 in Human Osteosarcoma CellsBiochemical and Biophysical Research Communications, 2000
- Inhibition of lung tumor cell growth in vitro and mouse lung tumor formation by lovastatinCancer Letters, 1996
- Effects of pravastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, on two human tumour cell linesZeitschrift für Krebsforschung und Klinische Onkologie, 1995
- Cytotoxicity of Simvastatin to Pancreatic Adenocarcinoma Cells Containing Mutant ras GeneJapanese Journal of Cancer Research, 1994
- Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genesCell, 1988